Iron supplement has strong potential ahead

Established in 2010, Solvotrin Therapeutics is seeking EII funding to launch its groundbreaking iron supplement in Europe next year, and in the United States the following year.

Chief executive Pat O’Flynn, a former Ernst & Young Entrepreneur of the Year finalist, said that Solvotrin Therapeutics’ primary focus is on “improving established therapies, making them better and safer, with the added advantage of patent protection linked to a defined market need”.

Outlining the company’s ...